p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event

Mangham, D. C.; Cannon, Alexander M.; Li, X Q; Komiya, Setsuro; Gebhardt, Mark C.; Springfield, Dempsey S.; Rosenberg, A E; Mankin, Henry J.

doi:10.1136/mp.48.2.m79

Cited by 12 publications

(17 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been anecdotal evidence for an association of alterations in the P53 pathway and recurrent or advanced stage ES/PNET. 11,13,36 In a univariate analysis of 38 patients, Mangham et al 14 found that the three patients with tumors that showed immunoreactivity for P53 in Ͼ 10% of cells had significantly shorter overall and disease free survival. More recently, Abudu et al 15 reported on a series of 52 patients, 7 of whom showed P53 expression in Ͼ 10% of cells; among the 45 patients with localized disease at the time of diagnosis, P53 overexpression Ͼ 10% (n ϭ 5 patients) was a significant negative factor in multivariate analyses of overall survival (P ϭ 0.01, RR ϭ 3.6) and disease free survival.…”

Section: Discussionmentioning

confidence: 99%

“…10 P53 alterations are detected in approximately 10% of tumor samples from patients with ES/PNET, [11][12][13] and the impact of such alterations on clinical outcome is beginning to be analyzed. 14,15 In the current study, we report on the interrelations of immunohistochemical evidence of P53 alteration, EWS-FLI1 fusion type, and response to chemotherapy, and their impact on overall survival in a series of 55 patients with ES/PNET.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of P53 status in Ewing sarcoma

Álava¹,

Antonescu²,

Panizo³

et al. 2000

Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Prognostic impact of P53 status in Ewing sarcoma

Álava¹,

Antonescu²,

Panizo³

et al. 2000

Cancer

View full text Add to dashboard Cite

“…Recent studies have indicated the presence of the p53 gene alteration in 4% to 13% of patients [17][18][19][20][21][22][23] and the p16 INK4a gene alteration in 12% to 26% of patients [23][24][25][26][27][28][29] with Ewing sarcoma. These data indicated the presence of the p53 gene alteration among 11% of patients, the p16 INK4a gene alteration among 17%, and either alteration among 24% of patients.…”

Section: Arfmentioning

confidence: 99%

“…These data indicated the presence of the p53 gene alteration among 11% of patients, the p16 INK4a gene alteration among 17%, and either alteration among 24% of patients. [17][18][19][20][21][22][23][24][25][26][27][28][29] It has been suggested that the presence of these alterations potentially is linked with a poor prognosis for patients with this disease. [21][22][23]27,29 In addition, the presence of metastasis at diagnosis defines an advanced stage of the disease and has been considered the most unfavorable prognostic factor.…”

Section: Arfmentioning

confidence: 99%

Prognostic significance of p16^INK4a alteration for Ewing sarcoma

Honoki¹,

Stojanovski²,

McEvoy³

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. Despite findings from individual studies regarding prognostic factors for Ewing sarcoma, no conclusive results have been produced, partly because of small sample sizes. The objective of the current study was to evaluate whether the presence of p16INK4a alteration is associated with a poorer prognosis in patients with Ewing sarcomas. METHODS. A review was conducted of publications that assessed associations between p16INK4a status and 2‐year survival among patients with Ewing sarcoma. The association between metastatic disease at initial diagnosis and 2‐year survival was evaluated by synthesizing data in the form of risk ratios. RESULTS. Of 11 studies that were identified in the initial search strategy, 6 studies, representing 188 patients, met the inclusion criteria and, consequently, were pooled for quantitative analyses. The estimated pooled risk ratio of p16INK4a aberration was 2.17 (95% confidence interval [95% CI], 1.55–3.03; P < .001), whereas the estimated pooled risk ratio of metastasis at diagnosis among the 164 eligible patients was 2.60 (95% CI, 1.71–3.97; P < .001). There was no statistically significant difference in the pooled estimated risk ratios of p16INK4a aberration for a poor prognosis between patients with and without metastasis at diagnosis (1.86 and 2.21, respectively; P > .59). CONCLUSIONS. The presence of p16INK4a alteration was a statistically significant predictor of prognosis for patients with Ewing sarcoma. Along with other prognostic factors, such as metastasis, the p16INK4a alteration may be a potential candidate for improving the risk‐stratifying strategy for patients with these tumors. © 2007 American Cancer Society.

show abstract

“…Mutations of the p53 gene have been implicated in a variety of carcinomas and sarcomas, and there is increasing evidence in the literature that these abnormalities are associated with high histological grade and adverse prognosis (Isola et al, 1992;Hsu et al, 1993;Toguchida et al, 1993;Cordon-Cardo et al, 1994;Mangham et al, 1995). We have used immunohistochemisty to investigate abnormalities of p53 gene protein in patients with primary EwingÕs sarcoma with a Overexpression of p53 protein in primary EwingÕs sarcoma of bone: relationship to tumour stage, response and prognosis view to determining its significance in the diagnosis and prognosis of this disease.…”

mentioning

confidence: 99%

Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis

et al. 1999

Self Cite

View full text Add to dashboard Cite

Summary Biopsy tissues of 52 patients with Ewing's sarcoma of bone treated between 1983 and 1993 were examined immunohistochemically to determine the significance of p53 protein in diagnosis and prognosis of Ewing's sarcoma. Mean age at diagnosis was 17 years (range 6-36) and minimum follow-up was 30 months. The tumours were located in the extremities and central bones in 35 and 17 patients respectively. Metastases were present in seven patients at diagnosis. Treatment consisted of chemotherapy, surgery and/or radiotherapy in all the patients. Overexpression of p53 protein was demonstrated in seven patients (14%). There was no relationship between expression of p53 and site of tumours. Patients who overexpressed p53 protein appeared to have more advanced diseases at diagnosis and poorer response to chemotherapy than those without p53 overexpression. The 5-year relapse-free survival and overall survival in patients without metastases at the time of diagnosis were 66% and 71%, respectively, in p53 protein-negative patients compared with 20% relapsefree and overall survival in those with p53 protein overexpression (P = 0.01). The poorer prognosis in p53 protein-positive patients was independent of site, local treatment or necrosis of the tumours (P < 0.05). Over-expression of p53 protein is an independent poor prognostic factor in Ewing's sarcoma of bone.

show abstract

p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event

Cited by 12 publications

References 15 publications

Prognostic impact of P53 status in Ewing sarcoma

Prognostic impact of P53 status in Ewing sarcoma

Prognostic significance of p16^INK4a alteration for Ewing sarcoma

Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis

Contact Info

Product

Resources

About

p53 overexpression in Ewing's sarcoma/primitive neuroectodermal tumour is an uncommon event

Cited by 12 publications

References 15 publications

Prognostic impact of P53 status in Ewing sarcoma

Prognostic impact of P53 status in Ewing sarcoma

Prognostic significance of p16INK4a alteration for Ewing sarcoma

Overexpression of p53 protein in primary Ewing’s sarcoma of bone: relationship to tumour stage, response and prognosis

Contact Info

Product

Resources

About

Prognostic significance of p16^INK4a alteration for Ewing sarcoma